- Home
- MURA
MURA
Mural Oncology plc
as 03-28-2025 4:00pm EST
Stocks
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
| Founded: | 2013 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 67.2M | IPO Year: | N/A |
| Target Price: | $13.00 | AVG Volume (30 days): | 417.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.12 - $5.02 | Next Earning Date: | 03-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 79.64% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Mural Oncology plc (MURA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Loew Caroline | MURA | Chief Executive Officer | Mar 3 '25 | Sell | $3.36 | 4,313 | $14,491.68 | 305,590 | |
| Keson-Brookes Maiken | MURA | See Remarks | Mar 3 '25 | Sell | $3.41 | 2,731 | $9,308.37 | 75,033 | |
| Goodman Vicki L | MURA | Chief Medical Officer | Feb 24 '25 | Sell | $3.89 | 13,186 | $51,293.54 | 54,763 |
Latest Mural Oncology plc News
MURA Breaking Stock News: Dive into MURA Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
GlobeNewswire
18 days ago
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
GlobeNewswire
a month ago
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Simply Wall St.
2 months ago
We Think Mural Oncology (NASDAQ:MURA) Needs To Drive Business Growth Carefully
GlobeNewswire
3 months ago
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
GlobeNewswire
4 months ago
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TipRanks
4 months ago
Raymond James Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks
GlobeNewswire
4 months ago
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Compare MURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MURA Mural Oncology plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.